

TECHNICAL DATA SHEET

CyFlow™ HLA-B7 Purified Anti-Hu; Clone BB7.1

REF AF692459

For Research Use Only.
Not for use in diagnostic or therapeutic procedures.

Specifications

Antigen	HLA-B7
Alternative Names	—
Clone	BB7.1
Clonality	monoclonal
Format	Purified
Host / Isotype	Mouse / IgG1
Species Reactivity	Human, Non-Human Primates
Negative Species Reactivity	—
Quantity [Concentration]	0.1 mg [1 mg/ml]
Immunogen	Papain solubilised HLA-A2, B7

Specificity

The mouse monoclonal antibody BB7.1 recognizes the HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

Application

Based on published sources, this antibody is suitable for the following applications:

- Flow cytometry

Storage Buffer

The reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.

Storage and Stability

Storage	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
Stability	Do not use after expiration date stamped on vial label.

Background Information

HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropathies. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22% of healthy Caucasian individuals.

References

- Trapani JA, Vaughan HA, Tait BD, McKenzie IF: Immunoradiometric assay for the rapid detection of HLA-B27. Immunol Cell Biol. 1988 Jan; 66 (3):215-9. < PMID: 3155158 >
- Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P: Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci USA. 1989 Apr; 86(7):2361-4. < PMID: 2784569 >
- Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA. 1993 Dec 1; 90(23):11307-11. < PMID: 8248244 >
- Rini BI, Selk LM, Vogelzang NJ: Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res. 1999 Oct; 5(10):2766-72. < PMID: 10537340 >

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

- Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA: Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. *Cancer Res.* 2001 Sep 15; 61(18):6868-75. < PMID: 11559563 >
- Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, Sherman ME, Alfaro M, Hutchinson ML, Morales J, Lorincz A, Burk RD, Carrington M, Erlich HA, Apple RJ: Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. *J Infect Dis.* 2001 Nov 15; 184(10):1310-4. < PMID: 11679920 >
- de la Salle H, Saulquin X, Mansour I, Klayme S, Fricker D, Zimmer J, Cazenave JP, Hanau D, Bonneville M, Houssaint E, Lefranc G, Naman R: Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). *Clin Exp Immunol.* 2002 Jun; 128(3):525-31. < PMID: 12067308 >
- Grunewald J, Eklund A, Olerup O: Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. *Am J Respir Crit Care Med.* 2004 Mar 15; 169(6):696-702. < PMID: 14656748 >
- Hofmann S, Glückmann M, Kausche S, Schmidt A, Corvey C, Lichtenfels R, Huber C, Albrecht C, Karas M, Herr W: Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. *Mol Cell Proteomics.* 2005 Dec; 4(12):1888-97. < PMID: 16112985 >
- Cortez-Gonzalez X, Sidney J, Adotevi O, Sette A, Millard F, Lemonnier F, Langlade-Demoyen P, Zanetti M: Immunogenic HLA-B7-restricted peptides of hTERT. *Int Immunol.* 2006 Dec; 18(12):1707-18. < PMID: 17077179 >
- Bhattacharya P, Sengupta S: Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03. *Tissue Antigens.* 2007 Oct; 70(4):283-93. < PMID: 17767549 >
- Harjacek M, Margetić T, Kerhin-Brkljacić V, Martinez N, Grubić Z: HLA-B*27/HLA-B*07 in combination with D6S273-134 allele is associated with increased susceptibility to juvenile spondyloarthropathies. *Clin Exp Rheumatol.* 2008 May-Jun; 26(3):498-504. < PMID: 18578977 >
- Lo Monaco E, Sibilio L, Melucci E, Tremante E, Suchànek M, Horejsi V, Martayan A, Giacomini P: HLA-E: strong association with beta2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. *Immunol.* 2008 Oct 15; 181(8):5442-50. < PMID: 18832701 >

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
 Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

The Safety Data Sheet for this product is available at www.sysmex-partec.com/services.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com